Solid Biosciences Inc.

SLDB · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
129
SEC Filings

Business Summary

PART I Item 1. Bu siness. Overview We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreichs ataxia (FA), SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy (TNNT2 DCM), ...

Next Earnings

Q2 FY2026 — expected 2026-09-28

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSLDBdiscussed_in_filing Cybersecurity
topic_mentionSLDBdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-115928EDGAR115K words
2025-03-062024-12-310000950170-25-034644EDGAR—
2024-03-132023-12-310000950170-24-030508EDGAR—
2023-03-232022-12-310000950170-23-009318EDGAR—
2022-03-142021-12-310001564590-22-009963EDGAR—
2021-03-152020-12-310001564590-21-013153EDGAR—
2020-03-122019-12-310001564590-20-010247EDGAR—
2019-03-132018-12-310001564590-19-007462EDGAR—
2018-03-292017-12-310001193125-18-100742EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-032025-09-300001193125-25-262818EDGAR70K words
2025-08-122025-06-300000950170-25-107279EDGAR—
2025-05-152025-03-310000950170-25-072560EDGAR—
2024-11-062024-09-300000950170-24-122247EDGAR—
2024-08-132024-06-300000950170-24-096130EDGAR—
2024-05-152024-03-310000950170-24-060034EDGAR—
2023-11-082023-09-300000950170-23-061096EDGAR—
2023-08-142023-06-300000950170-23-042371EDGAR—
2023-05-112023-03-310000950170-23-020851EDGAR—
2022-11-102022-09-300000950170-22-024163EDGAR—
2022-08-112022-06-300000950170-22-016643EDGAR—
2022-04-272022-03-310001564590-22-015867EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001193125-26-102489EDGAR2K words
2026-03-060001193125-26-096709EDGAR—
2025-11-030001193125-25-262795EDGAR—
2025-06-130000950170-25-086215EDGAR—
2025-05-150000950170-25-072792EDGAR—
2025-02-180001193125-25-028691EDGAR—
2025-02-180001193125-25-028146EDGAR—
2025-02-180001193125-25-028123EDGAR—
2024-06-110001193125-24-159143EDGAR—
2024-01-080001193125-24-003882EDGAR—

129 total filings indexed. 98 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001707502
TickerSLDB
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 066c3c556030c8332c5b7390b1714aefb5caafc2ca03b872e73f26dde75849ff
parent: 7f7f003b1e6e10b9709d7f854efd13b5ad079577a41d38afa98264b34ce2662c
content hash: bc72193994ed97fbf23d5bc95d67e74c4e8aa3651289860a93da4834b2657020
signed: 2026-04-13T04:47:28.505Z
sources: 21 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf